{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T16:31:18Z","timestamp":1774801878414,"version":"3.50.1"},"reference-count":79,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIA"],"DOI":"10.2147\/cia.s325026","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T04:20:26Z","timestamp":1652847626000},"page":"797-810","source":"Crossref","is-referenced-by-count":156,"title":["Role of Aducanumab in the Treatment of Alzheimer\u2019s Disease: Challenges and Opportunities"],"prefix":"10.2147","volume":"Volume 17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8288-4468","authenticated-orcid":true,"given":"Miguel","family":"Vaz","sequence":"first","affiliation":[]},{"given":"V\u00edtor","family":"Silva","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5225-6222","authenticated-orcid":true,"given":"Cristina","family":"Monteiro","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4297-5108","authenticated-orcid":true,"given":"Samuel","family":"Silvestre","sequence":"additional","affiliation":[]}],"member":"301","published-online":{"date-parts":[[2022,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Alzheimer\u2019s Association. 2021 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2021;17(3):327\u2013406. doi:10.1002\/alz.12328.","DOI":"10.1002\/alz.12328"},{"key":"ref2","unstructured":"World Health Organization. Global action plan on the public health response to dementia 2017\u20132025. Geneva:World Heal Organ; 2017: 27. Available from: http:\/\/www.who.int\/mental_health\/neurology\/dementia\/action_plan_2017_2025\/en\/. Accessed May 14, 2022."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ene.13439","volume":"25","author":"Lane","year":"2018","journal-title":"Eur J Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"Deture","year":"2019","journal-title":"Mol Neurodegener"},{"key":"ref5","unstructured":"U.S. Food and Drug Administration (FDA). FDA grants accelerated approval for Alzheimer\u2019s drug. FDA News Release; 2021. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-drug. Accessed November 14, 2021."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1080\/17460441.2020.1793755","volume":"15","author":"Pietro","year":"2020","journal-title":"Expert Opin Drug Discov"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","volume":"27","author":"Salloway","year":"2021","journal-title":"Nat Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"100988","DOI":"10.1016\/j.eclinm.2021.100988","volume":"38","author":"Sturchio","year":"2021","journal-title":"EClinicalMedicine"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/d41586-021-01546-2","volume":"594","author":"Landmark Alzheimer\u2019s","year":"2021","journal-title":"Nature"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jama.2021.11558","volume":"326","author":"Rubin","year":"2021","journal-title":"JAMA"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1682","volume":"374","author":"Walsh","year":"2021","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"105754","DOI":"10.1016\/j.phrs.2021.105754","volume":"171","author":"Nistic\u00f2","year":"2021","journal-title":"Pharmacol Res"},{"key":"ref15","unstructured":"Alzheimer\u2019s Forum Association. Aducanumab approved to treat Alzheimer\u2019s disease. Alzforum; 2021. Available from: https:\/\/www.alzforum.org\/news\/research-news\/aducanumab-approved-treat-alzheimers-disease. Accessed November 11, 2021."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1021\/acschemneuro.1c00393","volume":"12","author":"Hooker","year":"2021","journal-title":"ACS Chem Neurosci"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-021-00838-z","volume":"13","author":"Cummings","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"ref18","unstructured":"Alzheimer\u2019s Forum Association. FDA advisory committee throws cold water on aducanumab filing. Alzforum; 2020. Available from: https:\/\/www.alzforum.org\/news\/community-news\/fda-advisory-committee-throws-cold-water-aducanumab-filing. Accessed November 11, 2021."},{"key":"ref19","unstructured":"U.S. Food and Drug Administration (FDA). Combined FDA and applicant PCNS drugs advisory committee briefing document. Peripheral and Central Nervous System (PCNS) Drugs Advisory Committee Meeting. Online; 2020. Available from: https:\/\/www.fda.gov\/media\/143502\/download. Accessed November 14, 2021."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"n1503","DOI":"10.1136\/bmj.n1503","volume":"373","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.4161","author":"Salloway","year":"2021","journal-title":"JAMA Neurol"},{"key":"ref22","unstructured":"European Medicines Agency (EMA). Refusal of the marketing authorisation for Aduhelm (aducanumab). EMA; 2021. Available from: https:\/\/www.ema.europa.eu\/documents\/smop-initial\/refusal-marketing-authorisation-aduhelm-aducanumab_en.pdf. Accessed December 17, 2021."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069780","volume":"376","author":"Lythgoe","year":"2022","journal-title":"BMJ"},{"key":"ref24","unstructured":"Eisai. Japan\u2019s first committee on new drugs of the pharmaceutical affairs and food sanitation council seeks additional data; aducanumab remains under review. Eisai Global; 2021. Available from: https:\/\/www.eisai.com\/news\/2021\/news2021101.html. Accessed April 9, 2022."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"173554","DOI":"10.1016\/j.ejphar.2020.173554","volume":"887","author":"Vaz","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.3390\/molecules25071659","volume":"25","author":"Penke","year":"2020","journal-title":"Molecules"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"S567","DOI":"10.3233\/JAD-179941","volume":"64","author":"Cline","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00659","volume":"13","author":"Chen","year":"2019","journal-title":"Front Neurosci"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-24501-0","volume":"8","author":"Arndt","year":"2018","journal-title":"Sci Rep"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/s41594-020-0505-6","volume":"27","author":"Linse","year":"2020","journal-title":"Nat Struct Mol Biol"},{"key":"ref32","unstructured":"U.S. Food and Drug Administration (FDA). Aducanumab for the treatment of Alzheimer\u2019s disease: clinical overview of efficacy. Peripheral and Central Nervous System (PCNS) Drugs Advisory Committee Meeting. Online; 2020. Available from: https:\/\/www.fda.gov\/media\/143504\/download. Accessed November 14, 2021."},{"key":"ref33","first-page":"2576","volume":"11","author":"Bussiere","year":"2013","journal-title":"Neurodegener Dis"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.trci.2016.06.002","volume":"2","author":"Ferrero","year":"2016","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"key":"ref35","unstructured":"Biogen. EMERGE and ENGAGE topline results: two phase 3 studies to evaluate aducanumab in patients with early Alzheimer\u2019s disease. Clinical Trials on Alzheimer\u2019s Disease (CTAD). San Diego; 2019. Available from: https:\/\/investors.biogen.com\/static-files\/ddd45672-9c7e-4c99-8a06-3b557697c06f. Accessed November 14, 2021."},{"key":"ref36","unstructured":"Biogen. Biogen and eisai to discontinue phase 3 ENGAGE and EMERGE trials of aducanumab in Alzheimer\u2019s disease. Biogen; 2019. Available from: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-and-eisai-discontinue-phase-3-engage-and-emerge-trials. Accessed November 8, 2021."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/alz.12213","volume":"17","author":"Knopman","year":"2021","journal-title":"Alzheimers Dement"},{"key":"ref38","unstructured":"Biogen. Biogen plans regulatory filing for aducanumab in Alzheimer\u2019s disease based based on new analysis of larger dataset from phase 3 studies. Biogen. 2019. Available from: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-plans-regulatory-filing-aducanumab-alzheimers-disease. Accessed November 20, 2021."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.2021-7-3","volume":"10","author":"Tampi","year":"2021","journal-title":"Drugs Context"},{"key":"ref40","unstructured":"Belluck P, Robbins R. Three F.D.A. advisers resign over approval of Alzheimer\u2019s drug. The New York Times; 2021. Available from: https:\/\/www.nytimes.com\/2021\/06\/10\/health\/aduhelm-fda-resign-alzheimers.html. Accessed April 9, 2022."},{"key":"ref41","unstructured":"U.S. Food and Drug Administration (FDA). Accelerated Approval; 2021. Available from: https:\/\/www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priority-review\/accelerated-approval. Accessed April 10, 2022."},{"key":"ref42","unstructured":"Biogen. European medicines agency accepts Biogen\u2019s aducanumab marketing authorization application for Alzheimer\u2019s disease. Biogen; 2020. Available from: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/european-medicines-agency-accepts-biogens-aducanumab-marketing. Accessed November 23, 2021."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"n3127","DOI":"10.1136\/bmj.n3127","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"ref44","unstructured":"Biogen. Update on regulatory review of aducanumab in the European Union. Biogen. Available from: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/update-regulatory-submission-aducanumab-european-union.; 2021. Accessed April 9, 2022."},{"key":"ref45","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1212\/WNL.96.15_supplement.2448","volume":"96","author":"Castrillo-Viguera","year":"2021","journal-title":"Neurology"},{"key":"ref46","unstructured":"ClinicalTrials.gov. A study to evaluate safety and tolerability of aducanumab in participants with Alzheimer\u2019s disease who had previously participated in the aducanumab studies 221AD103, 221AD301, 221AD302 and 221AD205; 2020. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04241068?term=aducanumab&draw=2&rank=3. Accessed November 13, 2021."},{"key":"ref47","unstructured":"Biogen. ADUHELM ICARE AD-US study, the first real-world observational phase 4 study in Alzheimer\u2019s disease at AAIC 2021. Biogen; 2021. Available from: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-and-eisai-announce-design-aduhelm-icare-ad-us-study-first. Accessed November 13, 2021."},{"key":"ref48","unstructured":"ClinicalTrials.gov. An observational study of aducanumab-avwa in participants with Alzheimer\u2019s disease in the US - full text view - ClinicalTrials.gov; 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05097131?term=aducanumab&draw=2&rank=10. Accessed November 13, 2021."},{"key":"ref49","unstructured":"Biogen. Update on the phase 4 confirmatory study of ADUHELM\u00ae. Biogen; 2021. Available from: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/update-phase-4-confirmatory-study-aduhelmr. Accessed December 17, 2021."},{"key":"ref50","unstructured":"Biogen. Update on the Phase 4 ENVISION confirmatory study of ADUHELM\u00ae | biogen. Biogen; 2022. Available from: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/update-phase-4-envision-confirmatory-study-aduhelmr. Accessed January 29, 2022."},{"key":"ref51","unstructured":"U.S. Food and Drug Administration (FDA). ADUHELM: full prescribing information; 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761178s003lbl.pdf. Accessed November 14, 2021."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","volume":"16","author":"Greenberg","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/nejmoa1304839","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"101339","DOI":"10.1016\/j.arr.2021.101339","volume":"68","author":"Avgerinos","year":"2021","journal-title":"Ageing Res Rev"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s11481-016-9722-5","volume":"12","author":"Penninkilampi","year":"2017","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/ene.14484","volume":"28","author":"Gleason","year":"2021","journal-title":"Eur J Neurol"},{"key":"ref58","unstructured":"Biogen. New phase 3 data show positive correlation between ADUHELMTM treatment effect on biomarkers and reduction in clinical decline in Alzheimer\u2019s disease | biogen. Biogen; 2021. Available from: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/new-phase-3-data-show-positive-correlation-between-aduhelmtm?cid=osm-lkdn-ctad-um-alz-111121. Accessed November 28, 2021."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/hast.1264","volume":"51","author":"Fleck","year":"2021","journal-title":"Hastings Cent Rep"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1056\/nejmp2110468","volume":"385","author":"Alexander","year":"2021","journal-title":"N Engl J Med"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1126\/scitranslmed.aau5732","volume":"12","author":"La","year":"2020","journal-title":"Sci Transl Med"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2021.4654","volume":"79","author":"Leuzy","year":"2021","journal-title":"JAMA Neurol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3233\/JAD-215065","volume":"83","author":"Mukhopadhyay","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1001\/jama.2021.3854","volume":"325","author":"Alexander","year":"2021","journal-title":"J Am Med Assoc"},{"key":"ref65","unstructured":"Alzheimer\u2019s Forum Association. Aducanumab approved to treat Alzheimer\u2019s disease. Alzforum; 2021. Available from: https:\/\/www.alzforum.org\/news\/research-news\/aducanumab-approved-treat-alzheimers-disease. Accessed January 6, 2022."},{"key":"ref66","unstructured":"Institute for Clinical and Economic Review. ICER issues statement on the FDA\u2019s approval of aducanumab for Alzheimer\u2019s disease. ICER; 2021. Available from: https:\/\/icer.org\/news-insights\/press-releases\/icer-issues-statement-on-The-fdas-approval-of-aducanumab-for-alzheimers-disease\/. Accessed November 11, 2021."},{"key":"ref67","unstructured":"Biogen. Biogen announces reduced price for ADUHELM\u00ae to improve access for patients with early Alzheimer\u2019s disease | biogen. Biogen; 2021. Available From: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-announces-reduced-price-aduhelmr-improve-access-patients. Accessed January 9, 2022."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"e968","DOI":"10.1212\/WNL.0000000000013314","volume":"98","author":"Whittington","year":"2022","journal-title":"Neurology"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"398","DOI":"10.14283\/jpad.2021.41","volume":"8","author":"Cummings","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"ref70","unstructured":"Centers for Medicare & Medicaid Services. Monoclonal antibodies directed against amyloid for the treatment of Alzheimer\u2019s disease; 2022. Available from: https:\/\/www.cms.gov\/newsroom\/press-releases\/cms-finalizes-medicare-coverage-policy-monoclonal-antibodies-directed-against-amyloid-treatment. Accessed April 11, 2022."},{"key":"ref71","unstructured":"Belluck P. Medicare officially limits coverage of aduhelm to patients in clinical trials. The New York Times; 2022. Available from: https:\/\/www.nytimes.com\/2022\/04\/07\/health\/aduhelm-medicare-alzheimers.html. Accessed April 10, 2022."},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1,16","DOI":"10.1097\/01.nt.0000821676.02301.7a","volume":"22","author":"Butcher","year":"2022","journal-title":"Neurol Today"},{"key":"ref73","unstructured":"Association AF. On aduhelm, medicare agency gets pressure from all sides | ALZFORUM. Alzforum; 2022. Available from: https:\/\/www.alzforum.org\/news\/community-news\/aduhelm-medicare-agency-gets-pressure-all-sides. Accessed January 27, 2022."},{"key":"ref74","unstructured":"Association AF. CMS plans to limit aduhelm coverage to clinical trials | ALZFORUM. Alzforum; 2022. Available from: https:\/\/www.alzforum.org\/news\/research-news\/cms-plans-limit-aduhelm-coverage-clinical-trials. Accessed January 27, 2022."},{"key":"ref75","doi-asserted-by":"publisher","volume-title":"Progress in Molecular Biology and Translational Science","year":"2019","DOI":"10.1016\/bs.pmbts.2019.10.001"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejca.2021.08.012","volume":"157","author":"Lythgoe","year":"2021","journal-title":"Eur J Cancer"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1001\/jamainternmed.2021.4604","volume":"181","author":"Gyawali","year":"2021","journal-title":"JAMA Intern Med"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.3390\/ijms23042011","volume":"23","author":"Silvestro","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref79","unstructured":"Association AF. Aduhelm lowers tau; registry to track real-world performance | ALZFORUM. Alzforum; 2021. Available from: https:\/\/www.alzforum.org\/news\/conference-coverage\/aduhelm-lowers-tau-registry-track-real-world-performance. Accessed February 1, 2022."}],"container-title":["Clinical Interventions in Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=80866","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=80866","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T08:31:10Z","timestamp":1727253070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/role-of-aducanumab-in-the-treatment-of-alzheimers-disease-challenges-a-peer-reviewed-fulltext-article-CIA"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":79,"URL":"https:\/\/doi.org\/10.2147\/cia.s325026","relation":{},"ISSN":["1178-1998"],"issn-type":[{"value":"1178-1998","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}